Cardiac Insight gets $2.5M for its cardiac and respiratory sensing tech

Cardiac Insight

Cardiac Insight, which is a University of Washington spinoff focused on advanced cardiac and respiratory sensing and computing technologies, has closed a $2.5 million Series C funding round. The company will use the money to accelerate the market penetration of its CardeaScreen product and finalize the development of its wearable sensor technology.

CardeaScreen is a 12-lead electrocardiogram (ECG) exam which takes less than 20 seconds, and which helps identify young athletes who may be at risk for sudden cardiac arrest (SCA). Relying on patented wireless device and advanced analysis software, the system can assist physicians to determine the need for further evaluation prior to participation in strenuous activities.

“We are excited to have completed this funding and move forward with our near term FDA submission for our 7-day ECG Monitor and increasing the sales of our CardeaScreen 12-lead device,” Brad Harlow, Cardiac Insight’s CEO, said in a statement. “Cardiac Insights’ shareholders and our partners look forward to both products serving patients by the end of 2016.”

CardeaScreen algorithms have substantially reduced the rate of false positive indications, and have proven as a cost-effective screening solution for schools.

Cardiac Insight is also engaged in the development of single-use, patient-centric technologies to simplify and streamline complex diagnostic exams centered around cardiology and related practices.